Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 4.13B P/E - EPS this Y -6.00% Ern Qtrly Grth -
Income -460.47M Forward P/E -9.21 EPS next Y -3.20% 50D Avg Chg -17.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -11.00%
Dividend N/A Price/Book 11.80 EPS next 5Y - 52W High Chg -36.00%
Recommedations 3.00 Quick Ratio 10.12 Shares Outstanding 182.20M 52W Low Chg 16.00%
Insider Own 15.33% ROA -29.79% Shares Float 77.82M Beta 1.41
Inst Own 85.12% ROE -92.45% Shares Shorted/Prior 5.98M/6.36M Price 26.33
Gross Margin - Profit Margin - Avg. Volume 520,117 Target Price 43.40
Oper. Margin - Earnings Date Oct 30 Volume 2,422,080 Change -14.09%
About Cerevel Therapeutics Holdings,

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts. As of August 1, 2024, Cerevel Therapeutics Holdings, Inc. operates as a subsidiary of AbbVie Inc.

CERE Chatroom

User Image Cobre_Miner Posted - 11/12/24

@docholliday22 @History101 have to agree …. It makes more sense for $BMY to step up and establish a partnership, at least, to gain a lion’s share of the schizophrenia market for the next decade. $ABBV is reeling from their mistake with $CERE

User Image Cobre_Miner Posted - 11/11/24

@Princessofdoom you are right $CERE was a SCAM! Poor $ABBV should had made a deal with $RVPH

User Image betachaser Posted - 11/11/24

$VKTX ridiculous price action but not surprising given this is clinical stage biotech. Conservatively, $2 billion VK2809, $1 billion in cash, so this is being given roughly $3 billion for VK2735 which is best in class SC & Oral for Obesity. Boggles the mind how BP spent so much on garbage acquisitions like $cere and $sgen yet haven’t pounced on something as game changing as this yet.

User Image Pika_Capital Posted - 11/11/24

$ABBV $CERE $8b down the drain lol 🤡 Should have bought $NBIX for $15-20B

User Image Trading_Angels Posted - 1 month ago

Super trends BIOtechs 2025: Upstream Bio ($UPB) clinical-stage biotechnology company developing treatments for inflammatory diseases, focus on severe respiratory disorders. Its lead product, verekitug, targets the TSLP receptor, addressing a significant unmet medical need. The experienced management team and substantial financial backing position Upstream Bio favorably for future growth. Intellia Therapeutics ($NTLA) Pioneering CRISPR/Cas9-based gene-editing therapies. Outlook: promising clinical data suggest significant potential in treating genetic diseases. Cerevel Therapeutics ($CERE) Developing therapies for central nervous system disorders, including Parkinson's, epilepsy, and schizophrenia. Sufficient cash reserves, positioned for potential upside by 2025. Vertex Pharmaceuticals ($VRTX) Focus: Specializes in treatments for cystic fibrosis and is expanding into gene-editing therapies, robust pipeline and strategic collaborations.

User Image NoRisksNoFun Posted - 1 month ago

$ARKG but $SNTI $CERE are deep in red!

User Image quickaspeter Posted - 10/22/24

@TradingtooRetire @Idvst8 I believe $IOVA is little over 5% of their portfolio, while $CERE is their top holding.

User Image anesthesia_sleep Posted - 09/12/24

$NKGN Today announced POSITIVE phase 1 Data in Alzheimer’s Disease! NKGen’s cryopreserved autologous enhanced NK cell therapy for the treatment of moderate Alzheimer’s disease Here are the billion dollar Alzheimer’s companies: $BIIB with LEQEMBI $ITCI with Intra-Cellular Therapies for treating psychosis in Alzheimer’s $CERE hallucinations and delusions associated with Alzheimer's disease psychosis

User Image willdenton331 Posted - 08/27/24

$CERE thank you for a nice ride

User Image SaintJeremiah Posted - 08/14/24

$ABBV $CERE $MRNA 1000% upside & undervalued pulled back to the point of a gap up or squeeze, recently received fast track for pancreatic cancer

User Image DLBEE Posted - 08/09/24

@Nochtar Abbvie just bought $CERE for $45 a share on July 31 2024.

User Image G101SPM Posted - 08/08/24

$ABBV $CERE $45.00. TAKE PROFIT DAC (dollar average cost) $41.90 (4.18.24) PRINT 8.1.24 AbbVie announced that it has completed its acquisition of Cerevel Therapeutics $CERE. note: In December 2023, the companies signed a definitive agreement under which AbbVie agreed to acquire Cerevel for $45 per share in cash.

User Image BottomFishers Posted - 4 months ago

$KTTA Bears are getting forced out by EoD🔥 $VALE $CERE $SWN.DL1024 $SWIN

User Image Stock_Titan Posted - 4 months ago

$ABBV $CERE AbbVie Completes Acquisition of Cerevel Therapeutics https://www.stocktitan.net/news/ABBV/abb-vie-completes-acquisition-of-cerevel-f0y604h738kk.html

User Image tradingcalendar Posted - 07/31/24

Cerevel Therapeutics $CERE being acquired by AbbVie $ABBV - Shares of CERE to be delisted tonight after 8PM ET - Shareholders to receive $45.00 cash per share More information : https://www.sec.gov/Archives/edgar/data/1805387/000119312523290342/d509048ddefa14a.htm

User Image tradethehalt Posted - 07/31/24

$CERE trade halt (T12) was alerted to our Members at 7:50pm EDT. Halt price: $44.97 Vol: 15.04M.

User Image jbraun123 Posted - 07/31/24

$CERE Per DTC, expect payout to happen tmrw :) GLTA

User Image NVDAMillionaire Posted - 07/30/24

$CERE Cerevel Therapeutics Holdings, Inc. (CERE): A Promising Neuroscience Powerhouse Poised for Transformative Growth http://beyondspx.com/2024/07/30/cerevel-therapeutics-holdings-inc-cere-a-promising-neuroscience-powerhouse-poised-for-transformative-growth/

User Image flytrader1 Posted - 07/26/24

$CERE No news for months except for the FCC scare recently. They will release earnings shortly which most likely explains the rebound in price as the market anticipates that the deal will close in weeks.

User Image paiocje Posted - 07/18/24

$CERE Why is pre-market on YF and stocktwits showing $44 but IBKR says no change from close?

User Image paiocje Posted - 07/16/24

$CERE Is anyone actually active on this board? Remarkably quiet vs deals like SGEN

User Image gentleowl Posted - 07/15/24

$CERE tomorrow 43$

User Image TickerDD_com Posted - 5 months ago

From 6/17/2024, looking back across 21 Month-Ends for CERE, Percentage Change of Average Monthly Price had Equal (50%) while Percentage Change of Average Monthly Volume had All Positives (100%) $CERE #CERE #CEREStock #TickerDD #CEREPrice https://www.youtube.com/watch?v=VerL56oiKjI

User Image PeedyWeedy Posted - 06/29/24

$CERE Is there an upcoming data release for darigabat, if so, when it is expected? Thanks.

User Image KCSVEN Posted - 06/26/24

$CERE According to a Seeking Alpha article: "While there was no specific reason for the drop on Tuesday, some traders told Seeking Alpha there was some vague speculation out of unidentified broker that the FTC was gearing up for a lawsuit and that Cerevel (CERE) was increasingly looking like it may be the target for the regulator. Some people also attributed the weakness to the Russell index reconstitution on Friday and some options trades on Tuesday."

User Image OpenOutcrier Posted - 06/25/24

RECAP 6/25 Unusual Puts: $CERE Aug 40/35 P Spd $LW Aug 75 P Live Breaking trading news www.openoutcrier.com

User Image KCSVEN Posted - 06/25/24

$CERE FROM YAHOO BOARD Abbvie had their Parkinson’s drug turned down by the FDA today because they did not like what they found at the manufacturing plant run by a third-party unrelated company. The FDA said there are no issues at all with the actual drug and they are not making any requests for new studies or information about the drug, but yes, it could delay drug approval. people are probably worried that it will delay CERE’s drug as well, and if this would be considered a MAC that would allow abbvie to cancel the deal. Read the Delaware contract and you will see that that is not a MAC, even if they wanted out of the deal, and they do not. The contract specifies that drug approval is NOT a MAC, thus abbvie assumes all risk. This is simply people getting afraid, but they will quickly realize there’s no reason. Take advantage of it and buy some now. Even if the actual manufacturing and drug approval is delayed it has nothing to do with the timing of the buyout being finalized.

User Image TeresaTrades Posted - 06/25/24

Heavy options volume $PTEN $ITB $BMBL $CERE $FYBR

User Image flytrader1 Posted - 06/25/24

$CERE lots of bearish option action & implied volatility has jumped

User Image KCSVEN Posted - 06/25/24

$CERE Not good this close to when a close should be happening to be down 5% on heavy volume with a Bearish Put Spread put on right before the move. "Could" be a bear raid but also could be a sign some negative news is coming, best to be on sidelines and see what happens.

Analyst Ratings
Mizuho Neutral Feb 16, 24
JP Morgan Neutral Dec 28, 23
Jefferies Hold Dec 22, 23
TD Cowen Market Perform Dec 8, 23
HC Wainwright & Co. Neutral Dec 7, 23
Piper Sandler Neutral Dec 7, 23
Cantor Fitzgerald Neutral Dec 7, 23
Morgan Stanley Overweight Nov 2, 23
Piper Sandler Overweight Sep 28, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
DiPietro Kenneth Chief Human Resource.. Chief Human Resources Officer Dec 22 Sell 41.45 8,000 331,600 24,663 12/27/23
DiPietro Kenneth Chief Human Resource.. Chief Human Resources Officer Dec 22 Option 3.5 8,000 28,000 32,663 12/27/23
Bodenrader Mark See Remarks See Remarks Dec 19 Sell 41.42 7,889 326,762 17,724 12/21/23
DiPietro Kenneth Chief Human Resource.. Chief Human Resources Officer Dec 19 Sell 41.42 6,256 259,124 24,663 12/21/23
Akamine Scott Chief Legal Officer Chief Legal Officer Dec 19 Sell 41.42 7,072 292,922 7,237 12/21/23
Sanchez Ramiro Chief Medical Office.. Chief Medical Officer Dec 19 Sell 41.42 10,152 420,496 14,673 12/21/23
ALTSCHULLER Susan Chief Financial Offi.. Chief Financial Officer Dec 19 Sell 41.42 13,808 571,927 16,913 12/21/23
Tregoning Kathleen See Remarks See Remarks Dec 19 Sell 41.42 6,288 260,449 7,516 12/21/23
Akamine Scott Chief Legal Officer Chief Legal Officer Dec 05 Sell 38.19 17,500 668,325 513 12/07/23
Akamine Scott Chief Legal Officer Chief Legal Officer Dec 05 Option 13.17 17,500 230,475 10,513 12/07/23
COLES N ANTHONY Director Director Nov 07 Sell 25.09 27,176 681,846 2,704 11/09/23
COLES N ANTHONY Director Director Nov 07 Option 3.5 27,176 95,116 2,804 11/09/23
COLES N ANTHONY Director Director Nov 02 Sell 25.31 100,000 2,531,000 2,704 11/06/23
COLES N ANTHONY Director Director Nov 02 Option 3.5 100,000 350,000 64,105 11/06/23
PERCEPTIVE ADVISORS LLC Director Director Oct 16 Buy 22.81 876,808 19,999,990 10,794,876 10/17/23
Renaud Ronald C JR President & CEO President & CEO Aug 03 Buy 23.9552 83,857 2,008,811 83,857 08/07/23
Burgess Paul D. See Remarks See Remarks Aug 04 Buy 22.9339 21,880 501,794 21,880 08/07/23
COLES N ANTHONY Director Director Jul 11 Sell 30.03 50,000 1,501,500 2,704 07/13/23
COLES N ANTHONY Director Director Jul 11 Option 3.5 50,000 175,000 52,704 07/13/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Jun 01 Sell 32.6 50,000 1,630,000 2,704 06/05/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Jun 01 Option 3.5 50,000 175,000 52,704 06/05/23
Bodenrader Mark See Remarks See Remarks Jun 01 Sell 32.95 1,895 62,440 5,522 06/05/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Apr 11 Sell 25.06 50,000 1,253,000 2,704 04/13/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Apr 11 Option 3.5 50,000 175,000 52,704 04/13/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Feb 06 Sell 33.31 50,000 1,665,500 2,704 02/08/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Feb 06 Option 3.5 50,000 175,000 52,704 02/08/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Jan 05 Sell 30.33 50,000 1,516,500 2,704 01/06/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Jan 05 Option 3.5 50,000 175,000 52,704 01/06/23
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Dec 09 Option 3.5 50,000 175,000 52,704 12/13/22
COLES N ANTHONY CEO and Chairperson CEO and Chairperson Dec 09 Sell 26.86 50,000 1,343,000 2,704 12/13/22
PERCEPTIVE ADVISORS LLC Director Director Aug 16 Buy 35.00 1,425,000 49,875,000 6,511,727 08/18/22
Renger John Chief Scientific Off.. Chief Scientific Officer Aug 05 Option 3.5 30,000 105,000 12,704 08/09/22
Renger John Chief Scientific Off.. Chief Scientific Officer Aug 05 Sell 35.13 30,000 1,053,900 2,704 08/09/22
Akamine Scott Chief Legal Officer Chief Legal Officer Aug 08 Option 13.17 10,000 131,700 10,000 08/09/22
Akamine Scott Chief Legal Officer Chief Legal Officer Aug 08 Sell 40 10,000 400,000 08/09/22
Ceesay Abraham President President Aug 05 Sell 36.58 57,635 2,108,288 08/09/22
Ceesay Abraham President President Aug 05 Option 13.17 57,635 759,053 19,211 08/09/22
Renger John Chief Scientific Off.. Chief Scientific Officer Jul 05 Option 3.5 26,105 91,368 3,809 07/07/22
Renger John Chief Scientific Off.. Chief Scientific Officer Jul 05 Sell 31.25 26,105 815,781 2,704 07/07/22
Renger John Chief Scientific Off.. Chief Scientific Officer Apr 13 Option 3.5 45,000 157,500 46,980 04/15/22
Renger John Chief Scientific Off.. Chief Scientific Officer Apr 13 Sell 34.65 45,000 1,559,250 1,980 04/15/22
Renger John Chief Scientific Off.. Chief Scientific Officer Mar 16 Option 3.5 45,000 157,500 21,980 03/18/22
Renger John Chief Scientific Off.. Chief Scientific Officer Mar 16 Sell 31.25 45,000 1,406,250 1,980 03/18/22
Renger John Chief Scientific Off.. Chief Scientific Officer Feb 09 Option 3.5 25,000 87,500 26,980 02/11/22
Renger John Chief Scientific Off.. Chief Scientific Officer Feb 09 Sell 30 25,000 750,000 1,980 02/11/22
Renger John Chief Scientific Off.. Chief Scientific Officer Dec 15 Option 3.5 37,700 131,950 9,102 12/17/21
Renger John Chief Scientific Off.. Chief Scientific Officer Dec 15 Sell 31.67 37,700 1,193,959 1,980 12/17/21
PERCEPTIVE ADVISORS LLC Director Director Aug 25 Buy 27.36 175,585 4,804,006 5,018,680 08/25/21